<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="237808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003702</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0174</org_study_id>
    <secondary_id>NCI-2011-02026</secondary_id>
    <secondary_id>ECOG-G174</secondary_id>
    <secondary_id>CDR0000066809</secondary_id>
    <secondary_id>GOG-0174</secondary_id>
    <secondary_id>GOG-0174</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00003702</nct_id>
  </id_info>
  <brief_title>Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia</brief_title>
  <official_title>A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus &quot;Pulsed&quot; Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare the effectiveness of methotrexate with that of
      dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used
      in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
      die. It is not yet known whether methotrexate is more effective than dactinomycin in
      treating patients with gestational trophoblastic neoplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Compare the efficacy of methotrexate vs dactinomycin, as measured by complete response
      rate, in patients with low-risk gestational trophoblastic neoplasia.

      II. Compare the toxicity of these regimens in these patients. III. Determine whether the
      definition of persistent gestational trophoblastic neoplasia is accurate (as determined by
      the likelihood that the beta human chorionic gonadotropin [HCG] titer would decline on the
      day treatment is initiated).

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive methotrexate intramuscularly once weekly in the absence of disease
      progression or unacceptable toxicity.

      ARM II: Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of
      disease progression or unacceptable toxicity. All patients continue on treatment until 1
      beta human chorionic gonadotropin (HCG) titer is below the institutional normal. Patients
      then receive 1 additional consolidation treatment.

      Patients are followed every 4 weeks for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1999</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of observed adverse effects as assessed by the Gynecologic Oncology Group (GOG) toxicity criteria</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of objective (complete) response as measured by normal beta HCG levels</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate as measured by normal beta HCG levels</measure>
    <time_frame>Up to a minimum of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Good Prognosis Metastatic Gestational Trophoblastic Tumor</condition>
  <condition>Hydatidiform Mole</condition>
  <condition>Non-Metastatic Gestational Trophoblastic Tumor</condition>
  <condition>Uterine Corpus Choriocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (methotrexate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (dactinomycin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dactinomycin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (dactinomycin)</arm_group_label>
    <other_name>Actinomycin A IV</other_name>
    <other_name>Actinomycin C1</other_name>
    <other_name>ACTINOMYCIN D</other_name>
    <other_name>Actinomycin I1</other_name>
    <other_name>Actinomycin IV</other_name>
    <other_name>Actinomycin X 1</other_name>
    <other_name>Actinomycin-[thr-val-pro-sar-meval]</other_name>
    <other_name>Cosmegen</other_name>
    <other_name>DACT</other_name>
    <other_name>Dactinomycine</other_name>
    <other_name>Lyovac Cosmegen</other_name>
    <other_name>Meractinomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Arm I (methotrexate)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven low-risk gestational trophoblastic neoplasia (persistent
             hydatidiform mole or choriocarcinoma), defined as 1 of the following:

               -  Less than 10% decrease in the beta human chorionic gonadotropin (HCG) titer over
                  3 weekly titers

               -  Greater than 20% sustained rise in beta HCG titer over two consecutive weeks

               -  Persistently elevated beta HCG titer more than 4 months after initial curettage
                  (greater than 5 mIU/mL minimum)

               -  Histologically proven nonmetastatic choriocarcinoma

               -  Metastases to vagina, parametria, or lung (if no single pulmonary lesion is
                  greater than 2 cm)

          -  WHO score 0-6 (not including blood group or CT lung)

          -  No histologically confirmed placental site pseudotumor

          -  Must have undergone at least 1 uterine curettage

          -  Previously untreated disease

          -  Performance status - GOG 0-2

          -  WBC at least 3,000/mm^3

          -  Granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  SGPT and SGOT no greater than 3 times ULN

          -  Alkaline phosphatase no greater than 3 times ULN

          -  No significant prior abnormal hepatic function

          -  Creatinine no greater than 2.0 mg/dL

          -  No significant prior abnormal renal function

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for one year after study
             entry

          -  No other prior or concurrent malignancies within the past 5 years except
             nonmelanomatous skin cancer

          -  No prior chemotherapy for gestational trophoblastic neoplasia

          -  No concurrent curettage except as needed to control vaginal bleeding or to rule out
             placental site pseudotumor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Osborne</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 9, 2016</lastchanged_date>
  <firstreceived_date>November 1, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Choriocarcinoma</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
    <mesh_term>Hydatidiform Mole</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Dactinomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
